Segments - Cell Surface Markers Detection Market by Products (Flow Cytometry, Hematology Analyzers, Cell Imaging Systems, Reagents and Kits, and Other), Application (Disease Diagnosis and Identification, Research, and Drug Discovery, and Other), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2024 – 2032
The global cell surface markers detection market size was USD 5.7 Billion in 2023 and is likely to reach USD 12.5 Billion by 2032, expanding at a CAGR of 9.1% during 2024–2032. The market growth is attributed to the rising use of cell surface markers in cancer diagnostics.
Cell surface markers are molecules, typically proteins or carbohydrates, that are found on the outer surface of cells. They play a critical role in many cellular functions, including cell-to-cell communication, adhesion, and migration. Cell surface markers can be used to identify and characterize different cell types.
Cell surface markers are crucial in cell biology and medicine for identifying cell types, studying cell development and differentiation, diagnosing diseases such as cancer and monitoring treatment response. Growing need for precision medicine, rising use of diagnostics, and technological advancements pertaining to high throughput and automation are driving the market. Cell surface marker detection is vital in predicting patient responses to cancer drugs, aiding in point-of-care decisions.
In October 2022, according to a forecast by Macmillan Cancer Support, there were 3 million cancer cases worldwide in 2020, and that number is expected to rise to 5.3 million by 2040. Increase in cancer-related illnesses highlights the market's need for cell surface marker detection.
Artificial intelligence (AI) is expected to revolutionize the cell surface marker detection market by improving accuracy, efficiency, and automation. AI algorithms analyze complex data from sources such as microscopy images, flow cytometry data, and genetic information, identifying subtle patterns and variations in cell surface marker expression. This leads to accurate diagnoses and prognoses.
AI-powered automation streamlines workflows, freeing up researchers and lab technicians for more critical tasks. AI also identify novel cell surface markers, opening new avenues for disease diagnosis, drug development, and personalized medicine. Precision diagnostics developed using AI, allows for earlier and targeted treatment interventions. AI is used to design and test new drugs targeting specific cell surface markers associated with diseases, accelerating drug development and creating effective therapies.
Rising use of cell surface markers in disease diagnosis and identification is propelling the market. Cell surface markers play an important role in identification and differentiation of diseases such as cancer. Moreover, increasing preference of personalized medicine, as cell surface markers can identify unique cell surface marker profiles in patients.
High cost of instruments used for the cell surface marker detection is expected to hinder the market. Equipment such as cytometers and advance imaging systems are expensive, thus impeding the market. High initial investments costs limit the accessibility of these technologies for small research labs and clinics.
Development of point of care diagnostics is expected to boost the market during the forecast period. The emerging use of portable and user-friendly devices for cell surface marker detection is expected to contribute to the market. Growing focus on identifying and utilizing cell surface markers in bodily fluids such as blood, eliminates the need for invasive tissue biopsies. This offers a less-invasive approach for disease diagnosis and monitoring.
The market report includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Cell Surface Markers Detection Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2023 |
Historic Data |
2017–2022 |
Forecast Period |
2024–2032 |
Segmentation |
Products (Flow Cytometry, Hematology Analyzers, Cell Imaging Systems, Reagents & Kits, and Other) and Application (Disease Diagnosis & Identification, Research & Drug Discovery, and Other) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast |
Key Players Covered in the Report |
Agilent Inc.; BD Biosciences; Becton Dickinson and Company; BioLegend; Diasorin SpA; F. Hoffmann-La Roche Ltd.; Qiagen NV; Siemens Healthineers; Sigma-Aldrich; and Thermo Fisher Scientific Inc. |
Based on products, the cell surface markers detection market is divided into flow cytometry, hematology analyzers, cell imaging systems, reagents & kits, and other. The flow cytometry segment dominated the global market in 2023 owing to versatility and wide applications. The multiparameter analysis of cell including size, granularity, and presence of specific cell surface markers is expected to propel the segment significantly during the projection period. Moreover, the automation capabilities and established technologies is driving the segment.
The reagent & kits segment is anticipated to expand at a substantial CAGR during the forecast period owing to increasing demand. The reagents & kits are non-reusable; hence the continuous reorders are anticipated to fuel the segment. These consumables are essential for all cell surface marker detection techniques, including flow cytometry, immunohistochemistry (IHC), and Western blotting.
On the basis of application, the global market is segregated into disease diagnosis & identification, research & drug discovery, and other. The disease diagnosis & identification segment is anticipated to register a considerable CAGR during the forecast period owing to high demand for accurate diagnostics. The early detection and diagnostics are crucial for effective disease management and patient outcomes, thus driving the segment. Furthermore, growing focus on personalized medicine and increasing healthcare expenditure is expected to propel the segment during the projection period.
The research & drug discovery segment is projected to register a robust growth rate during the assessment years owing to drug target identification. Additionally, the understanding of disease management and development of companion diagnostics alongside novel drugs, which is expected to boost the segment during the forecast period.
In terms of region, the global cell surface markers detection market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market in 2023 owing to its top-notch infrastructure and excellent research services. Increasing R&D activities and growing investments by government organizations for the development of specific detection method are expected to propel the regional market. Furthermore, the presence of strong market players in this region and increasing number of product launch is expected to propel the market significantly. For instance,
In June 2021, Leica Microsystems launched the Leica Nano workflow, a new live-cell correlative light, and electron microscopy (CLEM) workflow solution designed to increase experimental success rates, improve reproducibility, and simplify light and electron microscopy (EM) integration.
The market in Asia Pacific is projected to grow at a significant pace in the coming years owing to increasing geriatric population. Growing number of cancer patient is driving the demand for specific diagnostic tests, which is propelling the regional market.
The cell surface markers detection market has been segmented on the basis of
Key players competing in the global cell surface markers detection market are Agilent Inc.; BD Biosciences; Becton Dickinson and Company; BioLegend; Diasorin SpA; F. Hoffmann-La Roche Ltd.; Qiagen NV; Siemens Healthineers; Sigma-Aldrich; and Thermo Fisher Scientific Inc.
These companies adopted development strategies including mergers, acquisitions, partnerships, collaboration, product launches, and production expansion to expand their consumer base worldwide. For instance,